Advertisement
American Journal of Kidney Diseases

Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT)

Published:November 20, 2017DOI:https://doi.org/10.1053/j.ajkd.2017.08.021

      Background

      Treating to a lower blood pressure (BP) may increase acute kidney injury (AKI) events.

      Study Design

      Data for AKI resulting in or during hospitalization or emergency department visits were collected as part of the serious adverse events reporting process of the Systolic Blood Pressure Intervention Trial (SPRINT).

      Setting & Participants

      9,361 participants 50 years or older with 1 or more risk factors for cardiovascular disease.

      Interventions

      Participants were randomly assigned to a systolic BP target of <120 (intensive arm) or <140 mm Hg (standard arm).

      Outcomes & Measurements

      Primary outcome was the number of adjudicated AKI events. Secondary outcomes included severity of AKI and degree of recovery of kidney function after an AKI event. Baseline creatinine concentration was defined as the most recent SPRINT outpatient creatinine value before the date of the AKI event.

      Results

      There were 179 participants with AKI events in the intensive arm and 109 in the standard arm (3.8% vs 2.3%; HR, 1.64; 95% CI, 1.30-2.10; P < 0.001). Of 288 participants with an AKI event, 248 (86.1%) had a single AKI event during the trial. Based on modified KDIGO (Kidney Disease: Improving Global Outcomes) criteria for severity of AKI, the number of AKI events in the intensive versus standard arm by KDIGO stage was 128 (58.5%) versus 81 (62.8%) for AKI stage 1, 42 (19.2%) versus 18 (14.0%) for AKI stage 2, and 42 (19.2%) versus 25 (19.4%) for AKI stage 3 (P = 0.5). For participants with sufficient data, complete or partial resolution of AKI was seen for 169 (90.4%) and 9 (4.8%) of 187 AKI events in the intensive arm and 86 (86.9%) and 4 (4.0%) of 99 AKI events in the standard arm, respectively.

      Limitations

      Trial results are not generalizable to patients with diabetes mellitus or without risk factors for cardiovascular disease.

      Conclusions

      More intensive BP lowering resulted in more frequent episodes of AKI. Most cases were mild and most participants had complete recovery of kidney function.

      Trial Registration

      Registered at ClinicalTrials.gov with study number NCT01206062.

      Graphical Abstract

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ambrosius W.T.
        • Sink K.M.
        • Foy C.G.
        • et al.
        The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).
        Clin Trials. 2014; 11: 532-546
        • Wright Jr., J.T.
        • Williamson J.D.
        • Whelton P.K.
        • et al.
        A randomized trial of intensive versus standard blood-pressure control.
        N Engl J Med. 2015; 373: 2103-2116
        • Behhdu S.
        • Rocco M.V.
        • Toto R.
        • et al.
        Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease: a secondary analysis of a randomized trial.
        Ann Intern Med. 2017; 167: 375-383
        • Cheung A.K.
        • Rahman M.
        • Reboussin D.M.
        • et al.
        Effects of intensive BP control in CKD.
        J Am Soc Nephrol. 2017; 28: 2721-2728
        • Levey A.S.
        • Coresh J.
        • Greene T.
        • et al.
        Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate.
        Ann Intern Med. 2006; 145: 247-254
        • Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease Work Group
        KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.
        Kidney Int Suppl. 2013; 3: 1-150
        • Lewington A.
        • Kanagasundaram S.
        Renal Association clinical practice guidelines on acute kidney injury.
        Nephron Clin Pract. 2011; 118: c349-c390
        • Bouchard J.
        • Soroko S.B.
        • Chertow G.M.
        • et al.
        Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury.
        Kidney Int. 2009; 76: 422-427
        • Grams M.E.
        • Sang Y.
        • Coresh J.
        • et al.
        Candidate surrogate end points for ESRD after AKI.
        J Am Soc Nephrol. 2016; 27: 2851-2859
        • Therneau T.M.
        • Grambsch P.M.
        Modeling Survival Data: Extending the Cox Model.
        Springer, New York, NY2000: 170-174
        • Chertow G.M.
        • Burdick E.
        • Honour M.
        • Bonventre J.V.
        • Bates D.W.
        Acute kidney injury, mortality, length of stay, and costs in hospitalized patients.
        J Am Soc Nephrol. 2005; 16: 3365-3370
        • Coca S.G.
        • Yusuf B.
        • Shlipak M.G.
        • Garg A.X.
        • Parikh C.R.
        Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis.
        Am J Kidney Dis. 2009; 53: 961-973
        • Zeng X.
        • McMahon G.M.
        • Brunelli S.M.
        • Bates D.W.
        • Waikar S.S.
        Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals.
        Clin J Am Soc Nephrol. 2014; 9: 12-20
        • Coca S.G.
        • Singanamala S.
        • Parikh C.R.
        Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis.
        Kidney Int. 2012; 81: 442-448
        • Lo L.J.
        • Go A.S.
        • Chertow G.M.
        • et al.
        Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease.
        Kidney Int. 2009; 76: 893-899
        • Hsu Cy
        • Iribarren C.
        • McCulloch C.E.
        • Darbinian J.
        • Go A.S.
        Risk factors for end-stage renal disease: 25-year follow-up.
        Arch Intern Med. 2009; 169: 342-350
        • Klahr S.
        • Levey A.S.
        • Beck G.J.
        • et al.
        The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.
        N Engl J Med. 1994; 330: 877-884
        • Wright Jr., J.T.
        • Bakris G.
        • Greene T.
        • et al.
        Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
        JAMA. 2002; 288: 2421-2431
        • Xie X.
        • Atkins E.
        • Lv J.
        • et al.
        Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.
        Lancet. 2016; 387: 435-443
        • Lewis J.B.
        Blood pressure control in chronic kidney disease: is less really more?.
        J Am Soc Nephrol. 2010; 21: 1086-1092
        • Sawhney S.
        • Mitchell M.
        • Marks A.
        • Fluck N.
        • Black C.
        Long-term prognosis after acute kidney injury (AKI): what is the role of baseline kidney function and recovery? A systematic review.
        BMJ Open. 2015; 5: e006497